Spyre Therapeutics Announces Grants of Inducement Awards

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) announced that its Compensation Committee approved inducement stock options to purchase 108,155 shares for employee Kate Chevlen in connection with her appointment as Chief Commercial Officer.

The grant was approved on January 22, 2026, provided under the 2018 Equity Inducement Plan, and was disclosed as material to the employee's acceptance under Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $34.09, equal to Spyre's Nasdaq closing price on January 22, 2026. Vesting is 1/4 on the first anniversary of the start date, then 1/48 monthly thereafter, subject to continuous service and the 2018 Plan terms.

News Market Reaction

+0.80%

1 alert

+0.80% News Effect

+$20M Valuation Impact

$2.47B Market Cap

0.3x Rel. Volume

On the day this news was published, SYRE gained 0.80%, reflecting a mild positive market reaction. This price movement added approximately $20M to the company's valuation, bringing the market cap to $2.47B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 108,155 shares Exercise price: $34.09 Option term: 10 years +2 more

5 metrics

Inducement options 108,155 shares Stock options granted to new Chief Commercial Officer

Exercise price $34.09 Strike equal to Nasdaq closing price on January 22, 2026

Option term 10 years Contract length of inducement stock options

Initial vesting 1/4 of shares Vests on first anniversary of employee’s start date

Ongoing vesting 1/48 monthly Remaining shares vest monthly thereafter, subject to service

Market Reality Check

Price: $31.98 Vol: Volume 847,466 is 1.4x th...

normal vol

$31.98 Last Close

Volume Volume 847,466 is 1.4x the 20-day average, indicating elevated trading activity before this filing. normal

Technical Shares trade above the 200-day MA of 20.12, reflecting a previously established uptrend.

Peers on Argus

Selected biotech peers showed mixed moves, with URGN up 4.49% and RAPP up 5.2%, ...

1 Up

Selected biotech peers showed mixed moves, with URGN up 4.49% and RAPP up 5.2%, while VERV was slightly down 0.09%. Momentum scanner only flagged QURE up 10.58%, suggesting company-specific factors rather than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Pipeline and outlook	Positive	+7.2%	Outlined six 2026 POC readouts and strong pro forma cash runway.
Jan 08	Inducement awards	Neutral	+1.6%	Granted 42,000 inducement options to six non‑executive employees.
Dec 05	Inducement awards	Neutral	+3.5%	Approved 20,300 inducement options for two non‑executive employees.
Nov 07	Inducement awards	Neutral	-1.5%	Granted 19,600 inducement options to one non‑executive employee.
Nov 04	Earnings and update	Positive	-0.6%	Reported Q3 2025 results and positive Phase 1 data with strong cash.

Pattern Detected

Inducement award announcements have generally coincided with modestly positive or muted stock reactions, while larger strategic/financial updates have produced more mixed responses.

Recent Company History

Over recent months, Spyre reported multiple inducement option grants alongside major strategic and clinical updates. A January 2026 outlook highlighted six expected Phase 2 proof‑of‑concept readouts and the hiring of Chief Commercial Officer Kate Tansey Chevlen, which preceded a 7.15% move. Earlier, Q3 2025 financials and clinical progress around SPY003 and Phase 2 platforms saw a mild negative reaction, while prior inducement grants in November and December 2025 drew small mixed price moves.

Market Pulse Summary

This announcement details a standard inducement stock option grant of 108,155 shares at an exercise ...

Analysis

This announcement details a standard inducement stock option grant of 108,155 shares at an exercise price of $34.09 with a 10‑year term and time‑based vesting, tied to the new Chief Commercial Officer’s appointment. It follows a series of similar grants disclosed in late 2025 and early 2026. Investors tracking Spyre’s story may focus more on upcoming clinical readouts and previously reported cash runway than on this routine compensation event.

Key Terms

stock options, equity inducement award, exercise price, vesting, +2 more

6 terms

stock options financial

"approved the grant of stock options to purchase 108,155 shares of common stock"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

equity inducement award financial

"in connection with her appointment as Chief Commercial Officer, as an equity inducement award"

An equity inducement award is a grant of company stock or stock-based rights given to a new employee as a hiring incentive, paid in addition to normal pay and benefit programs. It works like a signing bonus but in company shares, aligning the hire’s interests with shareholders while also increasing the number of outstanding shares; investors watch these awards for their impact on ownership dilution, executive motivation, and reported compensation costs.

exercise price financial

"an exercise price equal to $34.09, the closing price per share of Spyre's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"options granted to the employee shall vest and become exercisable as to one-fourth"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Nasdaq Listing Rule 5635(c)(4) regulatory

"material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity inducement plan financial

"under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended"

An equity inducement plan is a program that gives new hires or targeted employees stock, restricted shares, or stock options as a hiring or retention reward, often separate from the company’s regular long-term incentive plans. Think of it as a signing bonus paid in company stock: it helps attract and keep talent but matters to investors because it can dilute existing shares, change executive incentives, and affect future earnings through compensation expense.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 108,155 shares of common stock of Spyre to an employee, Kate Chevlen, in connection with her appointment as Chief Commercial Officer, as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on January 22, 2026 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $34.09, the closing price per share of Spyre's common stock as reported by Nasdaq on January 22, 2026. The options granted to the employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

For Investors :     
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

Who received the inducement award from Spyre Therapeutics (SYRE) on January 22, 2026?

An employee, Kate Chevlen, received the approved inducement award in connection with her appointment as Chief Commercial Officer.

How many stock options did Spyre (SYRE) grant and what is the exercise price?

Spyre granted options to purchase 108,155 shares with an exercise price of $34.09 per share.

What is the term and vesting schedule for the Spyre (SYRE) inducement stock options?

The options have a 10-year term. They vest 1/4 on the first anniversary of the employee's start date and then 1/48 monthly thereafter, subject to continuous service.

Under which plan were the Spyre (SYRE) inducement options granted?

The options were granted as an equity inducement under the Spyre Therapeutics 2018 Equity Inducement Plan, as amended.

Why was the Spyre (SYRE) option grant disclosed as material under Nasdaq rules?

The grant was disclosed as material to the employee's acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).

On what date was Spyre's closing stock price used to set the option exercise price?

The exercise price of $34.09 equals Spyre's Nasdaq closing price on January 22, 2026.